natgillin/translations-raw huggingface dataset:
Insulin Human Winthrop Infusat indeholder det aktive stof human insulin, som er fremstillet ved en bioteknokologisk proces og er identisk med kroppens eget insulin.
Insulin Human Winthrop Infusat contains the active substance insulin human which is made by a biotechnology process and is identical with the body's own insulin.
Insulin Human Winthrop Infusat må ikke anvendes i peristaltiske pumper med silikoneslanger.
Insulin Human Winthrop Infusat must not be used in peristaltic pumps with silicone tubing.
Insulin Human Winthrop Infusat må ikke blandes med andre insuliner eller insulin analoger.
Insulin Human Winthrop Infusat must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Infusat må ikke komme i direkte berøring med frostboks eller fryseelementer.
Do not put Insulin Human Winthrop Infusat next to the freezer compartment or a freezer pack.
Insulin Human Winthrop Infusat må ikke komme i direkte berøring med frostbokse eller fryseelementer.
Do not put Insulin Human Winthrop Infusat next to the freezer compartment or a freezer pack.
Insulin Human Winthrop Infusat må kun anvendes, såfremt opløsningen er klar, farveløs, uden synlige faste partikler og har et vandlignende udseende.
Insulin Human Winthrop Infusat must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of a water-like consistency.
Insulin Human Winthrop Infusat må kun anvendes, såfremt opløsningen er klar, farveløs, uden synlige partikler og har et vandlignende udseende.
Insulin Human Winthrop Infusat must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of a water-like consistency.
Insulin Human Winthrop Rapid 100 IE/ml injektionsvæske, opløsning, i cylinderampul
Insulin Human Winthrop Rapid 100 IU/ml solution for injection in a cartridge
Insulin Human Winthrop Rapid 100 IE/ml injektionsvæske, opløsning, i hætteglas
Insulin Human Winthrop Rapid 100 IU/ml solution for injection in a vial
Insulin Human Winthrop Rapid 40 IE/ml injektionsvæske, opløsning, i hætteglas
Insulin Human Winthrop Rapid 40 IU/ml solution for injection in a vial
Insulin Human Winthrop Rapid cylinderampuller må kun anvendes med følgende penne:
The Insulin Human Winthrop Rapid cartridges should only be used with the following pens:
Insulin Human Winthrop Rapid er en klar, farveløs opløsning til injektion i en fyldt pen, uden synlige faste partikler og med en vandlignende konsistens.
Insulin Human Winthrop Rapid is a clear, colourless solution for injection, with no solid particles visible, and of a water-like consistency.
Insulin Human Winthrop Rapid er en klar, farveløs opløsning til injektion, uden synlige faste partikler og med en vandlignende konsistens.
Insulin Human Winthrop Rapid is a clear, colourless solution for injection, with no solid particles visible, and of a water-like consistency.
Insulin Human Winthrop Rapid er en opløsning til injektion under huden eller, i særlige tilfælde, i en vene (blodåre).
Insulin Human Winthrop Rapid is a solution for injection under the skin.
Insulin Human Winthrop Rapid indeholder det aktive stof human insulin, som er fremstillet ved en bioteknokologisk proces og er identisk med kroppens eget insulin.
Insulin Human Winthrop Rapid contains the active substance insulin human which is made by a biotechnology process and is identical with the body's own insulin.
Insulin Human Winthrop Rapid indeholder:
What Insulin Human Winthrop Rapid contains
Insulin Human Winthrop Rapid injiceres under huden 15 til 20 min. før et måltid.
Insulin Human Winthrop Rapid is injected under the skin 15 to 20 minutes before a meal.
Insulin Human Winthrop Rapid kan blandes med alle human insulin formuleringer, men ikke med dem designet specifikt til brug i insulinpumper.
Insulin Human Winthrop Rapid may be mixed with all insulin human formulations, but not with those designed specifically for use in insulin pumps
Insulin Human Winthrop Rapid kan blandes med alle human insulin formuleringer, men ikke med dem designet specifikt til brug i insulinpumper.
Insulin Human Winthrop Rapid may be mixed with all insulin human formulations, but not with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Rapid må ikke blandes med anden medicin
Do not mix insulin with any other medicines.
Insulin Human Winthrop Rapid må ikke blandes med andre insuliner eller med insulin-analoger.
Insulin Human Winthrop Rapid must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Rapid må IKKE blandes med insulin af animalsk oprindelse eller insulin-analoger.
Also, it must NOT be mixed with animal source insulins or insulin analogues.
Insulin Human Winthrop Rapid må ikke komme i direkte berøring med frostboks eller fryseelementer.
Do not put Insulin Human Winthrop Rapid next to the freezer compartment or a freezer pack.
Insulin Human Winthrop Rapid må kun anvendes, såfremt opløsningen er klar, farveløs, uden synlige faste partikler og har et vandlignende udseende.
Insulin Human Winthrop Rapid must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of a water-like consistency.
Insulin Human Winthrop Rapid SoloStar 100 IE/ml injektionsvæske, opløsning Human insulin
Insulin Human Winthrop Rapid SoloStar 100 IU/ml solution for injection Insulin human
Insulin Human Winthrop Rapid SoloStar 100 IE/ml injektionsvæske, opløsning i en fyldt pen Human insulin
Insulin Human Winthrop Rapid SoloStar 100 IU/ml solution for injection in a pre-filled pen Insulin human
Insulin Human Winthrop Rapid Solostar 100 IE/ml injektionsvæske, opløsning, i en fyldt pen
Insulin Human Winthrop Rapid SoloStar 100 IU/ml solution for injection in a pre-filled pen.
Insulin Human Winthrop Rapid SoloStar 100 IE/ml injektionsvæske, opløsning, i en fyldt pen
Insulin Human Winthrop Rapid SoloStar 100 IU/ml, solution for injection in a pre-filled pen
Insulin Human Winthrop Rapid SoloStar er hvid med en farvet doseringsknap.
Insulin Human Winthrop SoloStar is white with a colour on the injection button.
Insulin Human Winthrop-serien består af hurtigtvirkende insulinopløsninger (Insulin Human Winthrop Rapid og Insulin Human Winthrop Infusat), der indeholder opløseligt insulin, en middellangt virkende insulinsuspension (Insulin Human Winthrop Basal), der indeholder isophaninsulin, og kombinationer af hurtigt- og middelangtvirkende insulin i forskellige blandingsforhold (Insulin Human Winthrop Comb):
The Insulin Human Winthrop range is comprised of fast-acting insulin solutions (Insulin Human Winthrop Rapid and Insulin Human Winthrop Infusat) that contain soluble insulin, an intermediate-acting insulin suspension (Insulin Human Winthrop Basal) that contains isophane insulin, and combinations of fast- and intermediate- acting in various proportions (Insulin Human Winthrop Comb):
Insulin human, rDNA (fremstillet ved rekombinant DNA-teknologi i Saccharomyces cerevisiae).
Insulin human, rDNA (produced by recombinant DNA technology in Saccharomyces cerevisiae).
Insulin i forskellige koncentrationer (f.eks.
Insulins of different concentration (e.g.
Insulin injicers ikke ved at dreje på dosisvælgeren.
Turning the dose selector will not inject insulin.
Insulin kan også forårsage natriumretention især hvis tidligere dårlig metabolisk kontrol er forbedret ved intensiveret insulinterapi
Insulin may also cause sodium retention, particularly if previously poor metabolic control is improved by intensified insulin therapy
Insulin lispro (rDNA)
Insulin lispro (rDNA origin)
Insulin lispro er fremstillet ved gensplejsning.
Insulin lispro is made in the laboratory by a ‘recombinant DNA technology’ process.
Insulin lispro er nært beslægtet med human insulin, der er et naturligt forekommende hormon, som produceres i bugspytskirtlen.
Insulin lispro is closely related to human insulin which is a natural hormone made by the pancreas.
Insulin lispro fås som Humalog i en opløselig form, som mere eller mindre virker umiddelbart efter injektion, og som Humalog Basal i form af en »protaminsuspension«, der optages langsommere og derfor virker længere.
Insulin lispro is available as Humalog in the soluble form, which acts more or less immediately after injection, and as Humalog Basal in the ‘protamine suspension’ form, which is absorbed much more slowly so that it works for longer.
Insulin lispro fås som Liprolog i en opløselig form, som mere eller mindre virker umiddelbart efter injektion, og som Liprolog Basal i form af en »protaminsuspension«, der optages langsommere og derfor virker længere.
Insulin lispro is available as Liprolog in the soluble form, which acts more or less immediately after injection, and as Liprolog Basal in the ‘protamine suspension’ form, which is absorbed much more slowly so that it works for longer.
Insulin lispro Humulin Regular
Insulin Lispro
Insulin lispro i Humalog BASAL findes uopløst i en væske med protaminsulfat.
The insulin lispro in Humalog BASAL is available in a suspension together with protamine sulphate.
Insulin lispro i Humalog BASAL KwikPen findes uopløst i en væske med protaminsulfat, så det virker i længere tid.
The insulin lispro in Humalog BASAL KwikPen is available in a suspension together with protamine sulphate, so that its action is prolonged.
Insulin lispro i Humalog BASAL KwikPen findes uopløst i en væske med protaminsulfat.
The insulin lispro in Humalog BASAL is available in a suspension together with protamine sulphate.
Insulin lispro i Liprolog Basal findes uopløst i en væske med protaminsulfat.
The insulin lispro in Liprolog Basal is available in a suspension together with protamine sulphate.
Insulin lispro i Liprolog Basal KwikPen findes uopløst i en væske med protaminsulfat, så det virker i længere tid.
The insulin lispro in Liprolog Basal KwikPen is available in a suspension together with protamine sulphate, so that its action is prolonged.
Insulin lispro i Liprolog Basal KwikPen findes uopløst i en væske med protaminsulfat.
The insulin lispro in Liprolog Basal is available in a suspension together with protamine sulphate.
Insulin lispro injektionsvæske, opløsning indeholdende 200 enheder/ml må ikke overføres fra den fyldte pen, KwikPennen, til en sprøjte.
The insulin lispro solution for injection containing 200 units/ml must not be transferred from the pre- filled pen, the KwikPen, to a syringe.
Insulin lispro injektionsvæske, opløsning indeholdende 200 enheder/ml må ikke overføres fra KwikPennen til andre insulindispenseringssystemer, inklusive insulininfusionspumper.
The insulin lispro solution for injection containing 200 units/ml must not be transferred from the KwikPen to any other insulin delivery device, including insulin infusion pumps.
Insulin lispro protaminsuspension (rDNA)
Insulin lispro protamine suspension (rDNA origin)
Insulin med gradvist indsættende og langvarig virkning
Insulin with a gradual onset and long duration of action.
Insulin med gradvist indsættende og langvarig virkning
Insulin with a rapid onset and moderately long duration of action.
Insulin med gradvist indsættende og langvarig virkning.
Insulin with a rapid onset and moderately long duration of action.
Insulin med hurtigt indsættende og middellang virkning.
Insulin with a rapid onset and moderately long duration of action.
Insulin må ikke blandes med andre lægemidler
Do not mix insulin with any other medicines.
Insulin må ikke blandes med andre lægemidler.
Do not mix insulin with any other medicine except with insulin human preparations as detailed below.
Insulin må ikke blandes med andre lægemidler.
Do not mix insulin with any other medicines except with insulin human preparations as detailed below.
Insulin og beta-cellestimulerende midler
Insulin and insulin secretagogues
insulin og perorale antidiabetika visse langtidsvirkende sulfonamider
insulin and oral antidiabetic products, certain long acting sulphonamides,
Insulin og sulfonylurinstoffer kan medføre hypoglykæmi.
Insulin and sulphonylureas are known to cause hypoglycaemia.
Insulin og ß-cellestimulerende midler såsom sulfonylurinstoffer medfører hypoglykæmi.
Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia.
Insulin suspensioner bør ikke tilsættes til infusionsvæsker.
Insulin suspensions should not be added to infusion fluids.
Insulin suspensioner må ikke administreres intravenøst..
Insulin suspensions are never to be administered intravenously.
Insulin, der indsprøjtes et sådant sted, virker måske mindre godt.
Insulin that you inject in such a site may not work very well.
Insulin, der injiceres et sådant sted, er måske ikke så virkningsfuldt.
Insulin that you inject in such a site may not work very well.
insulin, enten alene eller sammen med metformin.
insulin, either on its own or together with metformin.
Insulin, human, rDNA (fremstillet ved rekombinant DNA-teknologi i Saccharomyces cerevisiae).
Insulin human, rDNA (produced by recombinant DNA technology in Saccharomyces cerevisiae).
Insulin, humant (INH) N=236, 231, 233, 233, 235, 235, 226, 217, 208, 236.
INH N= 236, 231, 233, 233, 235, 235, 226, 217, 208, 236.
insulin, metformin eller andre lægemidler til behandling af diabetes mellitus
insulin, metformin or other medicines to treat diabetes mellitus
Insulin-
Insulin
Insulin- cylinder- ampul
Insulin cartridge
Insulin- cylinderampul
Insulin cartridge
Insulin- forbruget og de kliniske symptomer kan være identiske med dem ved pumpeunderlevering.
The insulin usage and clinical symptoms may be identical to those of pump under-delivery.
Insulin- glargin1
Insulin glargine1
insulin-antistoffer
Anti-insulin antibodies
Insulin-antistoffer
Insulin antobodies
Insulin-pen
Insulin pen
insulin; metformin, liraglutid, vildagliptin, nateglinid (medicin mod diabetes).
insulin; metformin, liraglutide, vildagliptin, nateglinide (antidiabetic medicines).
Insulinabsorptionen og den deraf følgende blodglucosesænkende virkning af en dosis kan variere mellem de forskellige injektionsfelter (f.eks. på abdomen i forhold til låret).
Insulin absorption and hence the blood–glucose-lowering effect of a dose may vary from one injection area to another (e.g. the abdominal wall compared with the thigh).
insulinafhængig diabetes diabetisk ketoacidose eller diabetisk prækoma.
insulin dependant diabetes diabetic ketoacidosis or diabetic coma.
Insulinanalog til måltid
Meal-time insulin analog
Insulinanalog til måltid +/- metformin
Meal-time insulin analog+/-metformin
Insulinanalog ved måltid
Meal-time insulin analogue
Insulinantistoffer
Antibodies to insulin
Insulinbehandlingen kan føre til forbigående væskeophobning i kroppen med hævede ankler og lægge.
Insulin treatment may cause temporary build-up of water in the body with swelling in the calves and ankles.
Insulinbehandlingen kan medføre at kroppen danner insulinantistoffer (stoffer, der reagerer mod insulin).
Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin).
Insulinbehandlingen kan medføre til at kroppen danner insulinantistoffer (stoffer, der reagerer mod insulin).
Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin).
Insulinbehovet falder normalt i første trimester og stiger siden i løbet af andet og tredje trimester.
Insulin requirements usually decrease in the first trimester and increase subsequently during the second and third trimester.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II receotor blokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants, (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulphate antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulphate antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide, or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE)- hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE)- hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f.eks. orale antidiabetika, salicylater (f.eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere, selektive serotoningenoptagshæmmere (SSRI)), visse angiotensin konverteringsenzym (ACE)- hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta-blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.